Impaza, tablets 20 pcs

Enhances endothelial NO synthase activity, restores endothelial production of nitric oxide (NO) during sexual stimulation, increases the content of cyclic guanosine-2 monophosphate (cGMP) in smooth muscles and promotes their relaxation, which leads to increased blood filling of cavernous bodies and provides an erection of sufficient strength and duration. The drug increases libido (libido) and sexual satisfaction. Regular use of the drug increases the level of testosterone in the serum (at a moderately reduced baseline< br>).

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis< br> (gas-liquid chromatography, high-performance liquid< br> Chromatography, chromatography-mass spectrometry) does not allow to estimate the content of the active ingredient of Impaza in biological fluids, organs and tissues due to the specific composition of the drug (see “Composition (1 tablet)”). See section “Composition (per tablet)”), which makes it technically impossible to study pharmacokinetics.

Indications

Impaza® is indicated for use in adults.
Erectile dysfunction (erectile dysfunction) of various origins.

Pharmacological effect

Pharmacotherapeutic group

Drugs for the treatment of erectile dysfunction.

ATX code

G04BE.

Pharmacological properties

Pharmacodynamics

Increases the activity of endothelial NO synthase, restores endothelial production of nitric oxide (NO) during sexual stimulation, increases the content of cyclic guanosine monophosphate (cGMP) in smooth muscles and promotes their relaxation, which leads to an increase in blood supply to the cavernous bodies and provides an erection of sufficient strength and duration.

The drug increases libido (sexual desire) and satisfaction with sexual intercourse. Regular use of the drug helps to increase testosterone levels in the serum (with a moderately reduced initial level).

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, gas chromatography-mass spectrometry) does not allow assessing the content of the active substance of the drug Impaza® in biological fluids, organs and tissues due to the specific composition of the drug
(see section “Composition (per 1 tablet)”), which makes it technically impossible to study pharmacokinetics.

Special instructions

Patients with rare hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take this drug.

Impact on the ability to drive vehicles and machinery
No negative effect of Impaza® on the ability to drive vehicles or other potentially dangerous mechanisms has been identified.

Active ingredient

Antibodies

Composition

Active ingredient:

affinity purified antibodies to endothelial NO synthase – 10,000 EMD*.

Excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.

* EMD – units of modifying action.

Pregnancy

According to its registered indication, the drug is not intended for use in women.

Side Effects

Individual hypersensitivity reactions to the components of the drug are possible.

Interaction

It is possible to use the drug Impaza® while taking nitrates in patients with coronary heart disease (angina pectoris
I-II functional class), as well as use in conjunction with beta-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, calcium antagonists.

Overdose

In case of overdose, dyspepsia may occur due to the excipients included in the drug.

Storage conditions

At a temperature not exceeding 25 °C.
Keep out of the reach of children.
During the period of use of the drug, store the blister pack in a cardboard box provided by the manufacturer.

Shelf life

3 years.
Do not use after expiration date.

Manufacturer

Materia Medica Holding, Russia